Fadi Abdel, Chief Development & Operations Officer, Speratum Biopharma Fadi Abdel is a biopharmaceutical executive with 25+ years of experience in clinical development, operations, and strategic innovation. As Chief Development & Operations Officer at Speratum Biopharma, he drives the advancement of miRNA-based oncology therapeutics, overseeing clinical strategy, execution, and business development. His leadership ensures seamless translation of groundbreaking science into transformative treatments for patients with solid tumors. Fadi has successfully led programs from proof of concept to late-stage development and commercialization. His expertise spans oncology, CNS, and immunology, with leadership roles at Alto Neuroscience, Johnson & Johnson, and Novartis. He has managed global clinical portfolios, spearheaded decentralized trials, and optimized R&D operations, delivering efficiency and scientific excellence. A visionary leader in precision medicine, Fadi is passionate about fostering innovation, accelerating clinical development, and driving strategic partnerships that shape the future of cancer care. Meet him at BIO International to explore collaboration opportunities in advancing next-generation oncology therapeutics.